<VariationArchive RecordType="classified" VariationID="1954646" VariationName="NM_024312.5(GNPTAB):c.1452dup (p.Gly485fs)" VariationType="Duplication" Accession="VCV001954646" Version="2" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2023-02-13" DateCreated="2023-02-07" MostRecentSubmission="2023-02-07">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="2014788" VariationID="1954646">
      <GeneList>
        <Gene Symbol="GNPTAB" FullName="N-acetylglucosamine-1-phosphate transferase subunits alpha and beta" GeneID="79158" HGNC_ID="HGNC:29670" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>12q23.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="12" Accession="NC_000012.12" start="101745499" stop="101830959" display_start="101745499" display_stop="101830959" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="12" Accession="NC_000012.11" start="102139274" stop="102224644" display_start="102139274" display_stop="102224644" Strand="-" />
          </Location>
          <OMIM>607840</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_024312.5(GNPTAB):c.1452dup (p.Gly485fs)</Name>
      <CanonicalSPDI>NC_000012.12:101766250:A:AA</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>12q23.2</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="12" Accession="NC_000012.12" start="101766250" stop="101766251" display_start="101766250" display_stop="101766251" variantLength="1" positionVCF="101766250" referenceAlleleVCF="C" alternateAlleleVCF="CA" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="12" Accession="NC_000012.11" start="102160028" stop="102160029" display_start="102160028" display_stop="102160029" variantLength="1" positionVCF="102160028" referenceAlleleVCF="C" alternateAlleleVCF="CA" />
      </Location>
      <ProteinChange>G485fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000012.11" sequenceAccession="NC_000012" sequenceVersion="11" change="g.102160029dup" Assembly="GRCh37">
            <Expression>NC_000012.11:g.102160029dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000012.12" sequenceAccession="NC_000012" sequenceVersion="12" change="g.101766251dup" Assembly="GRCh38">
            <Expression>NC_000012.12:g.101766251dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_021243.1" sequenceAccession="NG_021243" sequenceVersion="1" change="g.69617dup">
            <Expression>NG_021243.1:g.69617dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_024312.5" sequenceAccession="NM_024312" sequenceVersion="5" change="c.1452dup" MANESelect="true">
            <Expression>NM_024312.5:c.1452dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_077288.2" sequenceAccession="NP_077288" sequenceVersion="2" change="p.Gly485fs">
            <Expression>NP_077288.2:p.Gly485fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_024312.5(GNPTAB):c.1452dup (p.Gly485fs) AND multiple conditions" Accession="RCV002690096" Version="1">
        <ClassifiedConditionList TraitSetID="9397">
          <ClassifiedCondition DB="MedGen" ID="C2673377">Mucolipidosis type II</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0033788">Pseudo-Hurler polydystrophy</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2021-06-12" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2021-06-12" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2023-02-07" MostRecentSubmission="2023-02-07">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">19617216</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">25107912</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="9397" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="3038" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">ML II ALPHA/BETA</ElementValue>
                <XRef Type="MIM" ID="252500" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Mucolipidosis type II</ElementValue>
                <XRef ID="MONDO:0009650" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">I cell disease</ElementValue>
                <XRef ID="Mucolipidosis+II/3706" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mucolipidosis 2</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">ML 2</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Inclusion cell disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Leroy Disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">N-acetylglucosamine 1phosphotransferase deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">ML disorder type 2</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">ICD</ElementValue>
                <XRef Type="MIM" ID="252500" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">ML II</ElementValue>
                <XRef Type="MIM" ID="252500" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">GNPTA</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="keyword">GNPTAB-Related Mucolipidoses</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="6749" />
                <XRef ID="6749" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">GNPTAB-related disorders comprise the phenotypes mucolipidosis II (ML II) and mucolipidosis IIIa/ß (ML IIIa/ß), and phenotypes intermediate between ML II and ML IIIa/ß. ML II is evident at birth and slowly progressive; death most often occurs in early childhood. Orthopedic abnormalities present at birth may include thoracic deformity, kyphosis, clubfeet, deformed long bones, and/or dislocation of the hip(s). Growth often ceases in the second year of life; contractures develop in all large joints. The skin is thickened, facial features are coarse, and gingiva are hypertrophic. All children have cardiac involvement, most commonly thickening and insufficiency of the mitral valve and, less frequently, the aortic valve. Progressive mucosal thickening narrows the airways, and gradual stiffening of the thoracic cage contributes to respiratory insufficiency, the most common cause of death. ML IIIa/ß becomes evident at about age three years with slow growth rate and short stature; joint stiffness and pain initially in the shoulders, hips, and fingers; gradual mild coarsening of facial features; and normal to mildly impaired cognitive development. Pain from osteoporosis becomes more severe during adolescence. Cardiorespiratory complications (restrictive lung disease, thickening and insufficiency of the mitral and aortic valves, left and/or right ventricular hypertrophy) are common causes of death, typically in early to middle adulthood. Phenotypes intermediate between ML II and ML IIIa/ß are characterized by physical growth in infancy that resembles that of ML II and neuromotor and speech development that resemble that of ML IIIa/ß.</Attribute>
                <XRef ID="NBK1828" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301728</ID>
                <ID Source="BookShelf">NBK1828</ID>
              </Citation>
              <XRef ID="576" DB="Orphanet" />
              <XRef ID="C2673377" DB="MedGen" />
              <XRef ID="MONDO:0009650" DB="MONDO" />
              <XRef Type="MIM" ID="252500" DB="OMIM" />
            </Trait>
            <Trait ID="3039" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">ML IIIA</ElementValue>
                <XRef Type="MIM" ID="252600" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">ML III</ElementValue>
                <XRef Type="MIM" ID="252600" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">ML III ALPHA/BETA</ElementValue>
                <XRef Type="MIM" ID="252600" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Type III Mucolipidosis</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">ML 3 A</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Pseudo-Hurler polydystrophy</ElementValue>
                <XRef ID="Mucolipidosis+type+3A/4909" DB="Genetic Alliance" />
                <XRef ID="65764006" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mucolipidosis type 3A</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mucolipidosis III Alpha/Beta</ElementValue>
                <XRef ID="NBK1875" DB="GeneReviews" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">ML3</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="keyword">GNPTAB-Related Mucolipidoses</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">GNPTAB-related disorders comprise the phenotypes mucolipidosis II (ML II) and mucolipidosis IIIa/ß (ML IIIa/ß), and phenotypes intermediate between ML II and ML IIIa/ß. ML II is evident at birth and slowly progressive; death most often occurs in early childhood. Orthopedic abnormalities present at birth may include thoracic deformity, kyphosis, clubfeet, deformed long bones, and/or dislocation of the hip(s). Growth often ceases in the second year of life; contractures develop in all large joints. The skin is thickened, facial features are coarse, and gingiva are hypertrophic. All children have cardiac involvement, most commonly thickening and insufficiency of the mitral valve and, less frequently, the aortic valve. Progressive mucosal thickening narrows the airways, and gradual stiffening of the thoracic cage contributes to respiratory insufficiency, the most common cause of death. ML IIIa/ß becomes evident at about age three years with slow growth rate and short stature; joint stiffness and pain initially in the shoulders, hips, and fingers; gradual mild coarsening of facial features; and normal to mildly impaired cognitive development. Pain from osteoporosis becomes more severe during adolescence. Cardiorespiratory complications (restrictive lung disease, thickening and insufficiency of the mitral and aortic valves, left and/or right ventricular hypertrophy) are common causes of death, typically in early to middle adulthood. Phenotypes intermediate between ML II and ML IIIa/ß are characterized by physical growth in infancy that resembles that of ML II and neuromotor and speech development that resemble that of ML IIIa/ß.</Attribute>
                <XRef ID="NBK1828" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="3806" />
                <XRef ID="3806" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301728</ID>
                <ID Source="BookShelf">NBK1828</ID>
              </Citation>
              <XRef ID="423461" DB="Orphanet" />
              <XRef ID="577" DB="Orphanet" />
              <XRef ID="C0033788" DB="MedGen" />
              <XRef ID="MONDO:0018931" DB="MONDO" />
              <XRef Type="MIM" ID="252600" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="5685002" SubmissionDate="2023-01-11" DateLastUpdated="2023-02-07" DateCreated="2023-02-07">
        <ClinVarSubmissionID localKey="14056734|MedGen:C0033788;C2673377" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002991516" DateUpdated="2023-02-07" DateCreated="2023-02-07" Type="SCV" Version="1" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-06-12">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">19617216</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25107912</ID>
          </Citation>
          <Comment>This sequence change creates a premature translational stop signal (p.Gly485Trpfs*22) in the GNPTAB gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in GNPTAB are known to be pathogenic (PMID: 19617216, 25107912). This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals with GNPTAB-related conditions. For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GNPTAB" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000012.11:g.102160028_102160029insA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0033788" Type="CUI" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C2673377" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12506961</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="5685002" TraitType="Disease" MappingType="XRef" MappingValue="C0033788" MappingRef="MedGen">
        <MedGen CUI="C0033788" Name="Pseudo-Hurler polydystrophy" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5685002" TraitType="Disease" MappingType="XRef" MappingValue="C2673377" MappingRef="MedGen">
        <MedGen CUI="C2673377" Name="Mucolipidosis type II" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

